Want to see SE:IVACC full AI Analyst Report?
Intervacc AB (IVACC) Stock Price & Analysis
IVACC Stock Chart & Stats
- Day’s Range
- SEK 0.80 - SEK 0.88
- 52-Week Range
- SEK 0.57 - SEK 1.46
- Previous Close
- SEK 0.86
- Volume
- N/A
- Average Volume (3M)
- 404.35K
- Market Cap
- SEK 293.10M
- Enterprise Value
- SEK 317.65M
- Total Cash (Recent Filing)
- SEK 127.64M
- Total Debt (Recent Filing)
- SEK 866.00K
- Price to Earnings (P/E)
- ―
- Beta
- 0.38
- Next Earnings
- Nov 12, 2026 (Est.)
- EPS Estimate
- -0.06
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Very Low Leverage
A near-zero debt-to-equity position reduces fixed financial obligations and refinancing exposure. This conservative structure gives Intervacc greater flexibility to manage operating volatility and pursue development or commercialization priorities without the additional pressure of substantial interest-bearing debt.
Substantial Equity Base
A substantial equity base provides financial support while Intervacc develops and commercializes veterinary products. Although the company is not yet self-funding, this capital structure can extend its operating runway and reduce dependence on immediate borrowing during periods of investment.
Focused Veterinary Vaccine Business
The company has a defined commercial focus in veterinary pharmaceuticals rather than a broad, unfocused portfolio. Its marketed canine vaccine provides an established product platform and a route to recurring sales through veterinary clinics and animal-health distribution channels.
Bears Say
Recent Revenue Decline
The latest trailing-period revenue decline indicates that commercial uptake has not yet developed into a consistently expanding growth trend. Sustained weakness in sales would constrain operating leverage, reduce resources available for development, and make the path to durable profitability more difficult.
Persistent Unprofitability
Negative gross profit and substantial operating losses show that the current business model has not yet achieved sustainable unit economics at the reported scale. Continued losses can consume capital, limit reinvestment capacity, and leave future results dependent on improved product economics or stronger sales.
Ongoing Cash Burn
Persistent negative operating and free cash flow means Intervacc is not currently financing its activities from internally generated cash. If losses and investment needs continue, the company may require additional funding, creating pressure on liquidity and future capital allocation.
Intervacc AB News
IVACC FAQ
What was Intervacc AB’s price range in the past 12 months?
What is Intervacc AB’s market cap?
When is Intervacc AB’s upcoming earnings report date?
How were Intervacc AB’s earnings last quarter?
Is Intervacc AB overvalued?
Does Intervacc AB pay dividends?
What is Intervacc AB’s EPS estimate?
How many shares outstanding does Intervacc AB have?
What happened to Intervacc AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Intervacc AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Intervacc AB
Intervacc AB (publ) is a Swedish biotechnology company primarily engaged in the research and development of innovative vaccines designed to combat bacterial infections in animal health. The firm's vaccine pipeline targets various animals, including horses, piglets, and dairy cows, with its key product, Strangvac, specifically developed to prevent equine strangles. Beyond its current offerings, Intervacc is also advancing vaccines against Streptococcus suis and Staphylococcus aureus infections. In addition to vaccine development, the company distributes veterinary medicines and provides essential diagnostic services in veterinary bacteriology to clinics and stud farms. Headquartered in Hägersten, Sweden, Intervacc serves customers across the Nordic countries and the Baltic states.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Carl-Johan Dalsgaard
- Employees
- 16
- Website
- www.intervacc.se
- Address
- Västertorpsvägen 135, Hägersten, AB, 129 44, SE
Intervacc AB (IVACC) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 6 | 11 |
| Technical Analysis | 2 | 6 | 1 |
| Moving Averages | 2 | 0 | 10 |


